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Inflammation is considered a mechanistic driver of Alzheimer’s disease, thought
to increase tau phosphorylation, the first step to the formation of neurofibrillary
tangles (NFTs). To further understand how inflammation impacts the development
of tau pathology, we used (hTau) mice, which express all six, non-mutated, human
tau isoforms, but with an altered ratio of tau isoforms favoring 3R tau due to
the concomitant loss of murine tau (mTau) that is predominantly 4R. Such an
imbalance pattern has been related to susceptibility to NFTs formation, but whether
or not this also affects susceptibility to systemic inflammation and related changes
in tau phosphorylation is not known. To reduce the predominance of 3R tau by
increasing 4R tau availability, we bred hTau mice on a heterozygous mTau background
and compared the impact of systemic inflammation induced by lipopolysaccharide
(LPS) in hTau mice hetero- or homozygous mTau knockout. Three-month-old male
wild-type (Wt), mTau+/−, mTau−/−, hTau/mTau+/−, and hTau/mTau−/− mice were
administered 100, 250, or 330 µg/kg of LPS or its vehicle phosphate buffer saline
(PBS) [intravenously (i.v.), n = 8–9/group]. Sickness behavior, reflected by behavioral
suppression in the spontaneous alternation task, hippocampal tau phosphorylation,
measured by western immunoblotting, and circulating cytokine levels were quantified
4 h after LPS administration. The persistence of the LPS effects (250 µg/kg) on
these measures, and food burrowing behavior, was assessed at 24 h post-inoculation
in Wt, mTau+/−, and hTau/mTau+/− mice (n = 9–10/group). In the absence of
immune stimulation, increasing 4R tau levels in hTau/mTau+/− exacerbated pS202 and
pS396/404 tau phosphorylation, without altering total tau levels or worsening early
behavioral perturbations characteristic of hTau/mTau−/− mice. We also show for the
first time that modulating 4R tau levels in hTau mice affects the response to systemic
inflammation. Behavior was suppressed in all genotypes 4 h following LPS administration,
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but hTau/mTau+/− exhibited more severe sickness behavior at the 100 µg/kg dose
and a milder behavioral and cytokine response than hTau/mTau−/− mice at the
330 µg/kg dose. All LPS doses decreased tau phosphorylation at both epitopes in
hTau/mTau+/− mice, but pS202 levels were selectively reduced at the 100 µg/kg dose
in hTau/mTau−/− mice. Behavioral suppression and decreased tau phosphorylation
persisted at 24 h following LPS administration in hTau/mTau+/− mice.
Keywords: inflammation, lipopolysaccharide, Alzheimer’s disease, mouse model, tauopathies, tau
isoform imbalance
INTRODUCTION
Alzheimer’s disease (AD), the most prevalent senile dementia, is
characterized by the presence of amyloid beta (Aβ) plaques and
neurofibrillary tangles (NFTs) caused by hyperphosphorylation
and aggregation of the microtubule associated protein tau.
Their progressive accumulation is associated with cognitive
deterioration, brain atrophy, and neuroinflammation, but tau
pathology correlates better with disease progression than Aβ
deposition (1, 2). The adult human brain expresses six main
tau isoforms, which can be categorized as 3R or 4R tau based
on whether they contain three or four carboxy-terminal repeat
domains (3). In the healthy brain, the 3R and 4R isoforms are
found in equal amounts (4). However, alterations in the 4R:3R
tau isoform ratio, often caused by mutations in the tau gene,
trigger pathological tau aggregation and NFT formation (5).
Resulting tauopathies are classified in three groups according to
the predominant species of tau that accumulate: 4R tauopathies
(e.g., progressive supranuclear palsy, corticobasal degeneration),
3R tauopathies (e.g., Pick’s disease), and 3R+4R tauopathies
(e.g., AD) (6, 7); but in AD, the trigger of tau pathology is
not genetic. NFTs of AD patients express both isoforms, and
a number of studies reported a 4R:3R ratio of ∼1, comparable
to control brains (4, 8–10), suggesting that tau aggregation in
AD is not due to isoform imbalance. Nevertheless, changes
in the 4R:3R tau isoform ratio in AD brains have also been
reported with borderline to significant increases (11–15) or
decreases (16, 17) compared to controls. Importantly, this ratio is
subject to significant variability between AD samples. To clarify
these discrepancies, more detailed analyses have looked at the
differential accumulation of 3R and 4R tau in the human brain
in relation to AD severity (17, 18), to the brain areas investigated
(11, 13, 16), and to region-specific differences in susceptibility to
NFT formation within the brain (16), as well as in the NFTs of
AD patients where three distinct isoform patterns of tau coexist,
containing either 3R tau, 4R tau or both. Shifts in patterns
between neurons and brain regions were found to be associated
with the stage of NFT pathology (19–22). Overall, these detailed
studies suggest that the predominance of 3R tau over 4R tau
increases with the progression of NFT pathology.
The causes of sporadic AD are far from being fully understood,
but systemic inflammation is now seen as a key mechanistic
driver of AD pathogenesis. Genes associated with immune cell
function and susceptibility to inflammatory diseases (23, 24) as
well as systemic inflammatory conditions such as rheumatoid
arthritis, Type 2 diabetes, and obesity (25–27) increase the risk
of developing AD. Circulating levels of systemic inflammatory
mediators such as interleukin 1β (IL-1β) and tumor necrosis
factor alpha (TNFα) were found chronically upregulated in
AD (28). Post-mortem examinations of AD brains show a
sustained activation of immune cells, particularly surrounding
NFTs (29). Moreover, systemic infections accelerate the rate
of cognitive decline in AD patients, even after the resolution
of the initial inflammatory insult (30, 31). One potential
mechanism mediating the impact of systemic inflammation on
AD progression is through the exacerbation of tau pathology.
Kinases involved in tau phosphorylation, such as cyclin-
dependent kinase-5 and mitogen activated kinases, can be
induced by inflammatory signaling cascades (32–34). A number
of preclinical mouse studies using lipopolysaccharide (LPS) to
mimic gram-negative bacterial infection reported exacerbation of
tau pathology. For instance, a systemic LPS dose of 10 mg/kg was
found to increase tau phosphorylation in wild-type (Wt) mice,
whereas exacerbation of tau hyperphosphorylation was seen with
10 times less LPS (1 mg/kg) in hTau mice (35), a mouse line
expressing exclusively the six human tau isoforms (36). At 0.5
mg/kg, LPS was also found to increase tau phosphorylation and
aggregation in the 3xTg model, which expresses both tau and Aβ
pathology (37, 38). Yet, these preclinical studies have used high
LPS doses more relevant to sepsis than to the chronic low-grade
inflammation associated with AD (39).
LPS is an endotoxin produced in the gut and a potent
stimulator of the innate immune system. At low doses able to
induce physiologically relevant inflammation, LPS does not enter
the brain in the absence of blood–brain barrier dysfunction
(40, 41). Recent reports indicate that circulating concentrations
and brain penetration of LPS increase in AD patients, in which
LPS co-localizes with Aβ plaques and neurons (42–44). This
led to the hypothesis that endogenous LPS accumulation could
play a critical role in the pathophysiology of sporadic AD (45).
There is, therefore, a need to better understand the mechanisms
whereby systemic LPS affects tau pathology. Here we focused
on the impact on tau phosphorylation at the onset of systemic
inflammation with a low dose of LPS, using the hTau model.
This mouse line is thought to be the most relevant tau model
for AD. It involves the expression of all six, non-mutated, human
tau isoforms, but the altered ratio of tau isoforms favoring 3R
tau due to the concomitant loss of murine tau (mTau) that is
predominantly 4R is thought to underlie pathological changes
in this model (36). In favor of this hypothesis, restoring tau
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isoform imbalance to a 4R:3R ratio of ∼1 by increasing 4R
tau levels was found to alleviate tau pathology and cognitive
deficits in these mice (46). On the other hand, increasing 4R
tau and decreasing 3R tau expression without altering total
tau levels was found to worsen tau pathology and associated
behavioral deficits in hTau mice (47). And although removal of
mTau was found necessary for the tau pathology to occur in
hTau mice (36), we have shown previously that heterozygous
deletion of mTau is sufficient for robust behavioral deficits and
tau phosphorylation to occur in this model (48). While these
data show that direct modulation of the 4R:3R ratio in the brain
of hTau mice alters tau pathology, whether or not this also
affects susceptibility to systemic inflammation and LPS-induced
changes in tau phosphorylation is currently not known.
To address this question, we bred hTaumice on a heterozygous
mTau background (hTau/mTau+/−) to reduce the predominance
of 3R tau by increasing availability of 4R tau. We predicted that
this would alleviate behavioral and pathological changes in hTau
mice and protect them against exacerbation of tau pathology
after mild systemic inflammation with LPS. Here, we first report
that increased 4R tau levels in hTau/mTau+/− mice exacerbate
tau hyperphosphorylation compared to hTau mice on a full
mTau knockout background (hTau/mTau−/−). Since systemic
inflammation is expected to be an early event in the pathogenesis
of AD, we used 3-month-old mice, corresponding to the onset
of behavioral changes in these models (48, 49). We also report
that increasing 4R tau availability was associated with a rapid
reduction in tau phosphorylation in the hippocampus, seen 4 h
after inoculation with low doses of LPS, and persisting for at
least 24 h.
METHODS
Animals
Breeding stock of hTau mice on a C57/BL6J background
and their mTau−/− control [STOCK Mapttm1(EGFP)Klt
Tg(MAPT)8cPdav/J] were originally purchased from The
Jackson Laboratory (Bar Harbor, ME, USA, stock #005491). They
were then crossed with Wt C57/BL6J mice to produce mTau+/−
and hTau/mTau+/− breeders in the University of Nottingham
Biomedical Service Unit. This enabled the production of all
experimental animals from five genotypes as littermates: Wt,
mTau+/−, mTau−/−, hTau/mTau+/−, and hTau/mTau−/−.
Previous studies investigating the impact of modulation of
the 4R:3R tau isoform ratio on tau pathology have used either
males (46) or both males and females but without testing
for sex differences (47), although sex differences in disease
progression have been reported in hTau mice (50). As we did
not have an a priori hypothesis on sex differences in the impact
of 4R tau availability on immune responses, we only used male
mice for this study. They were maintained under standard
husbandry conditions on a 12/12 h light cycle, with lights on
at 07:00 h and room temperature, relative humidity, and air
exchange automatically controlled. Mice were kept grouped
housed in individually ventilated cages (IVCs) with ad libitum
access to food and water, and provided with a play tube and
nesting material. All animal procedures were carried out in
accordance with the UK Animals Scientific Procedures Act
under project license 40/3601, approved by the University of
Nottingham Animal Welfare and Ethical Review Board and
reported according to the ARRIVE guidelines (51). All analyses
were performed blind.
Drug Treatment
LPS (Escherichia coli serotype Sigma0111:B4, Sigma Aldrich) was
dissolved in phosphate buffer saline (PBS, Sigma Aldrich) and
stored in aliquots at −20◦ until use. The day of the experiment,
mice were injected intravenously (i.v.) in the dorsal tail vein with
100, 250, or 330 µg/kg of LPS or its vehicle PBS at a volume of 1
µl/g of body weight, as previously described (52). These doses
were selected to mimic a low-grade systemic inflammation as
seen in AD patients. They were previously shown to induce a
mild transient sickness syndrome associated with the expression
of pro-inflammatory mediators, reversible by anti-inflammatory
drugs (53, 54).
Study Design
Comparison of Tau Pathology in 9-Month-Old
hTau/mTau+/− and hTau/mTau−/− Mice
To assess the impact of increasing 4R tau availability on tau
aggregation, we used 9-month-old naïve male Wt, mTau+/−,
mTau−/−, hTau/mTau+/−, and hTau/mTau−/− mice (n =
4/group), an age when sarkosyl-insoluble tau can be expected
in the brain of hTau mice (36). Animals were sacrificed
by cervical dislocation; one hemisphere was snap-frozen for
subsequent assessment of sarkosyl-insoluble tau, while the
other hemisphere was fixed in 4% paraformaldehyde (PFA)
for 6 h at room temperature and paraffin embedded for
immunohistological analyses.
Dose-Dependent Effects of LPS on Sickness
Symptoms, Circulating Cytokine Levels, and Tau
Phosphorylation in hTau/mTau+/− and hTau/mTau−/−
Mice at Onset of Systemic Inflammation
Three-month-old maleWt, mTau+/−, mTau−/−, hTau/mTau+/−,
and hTau/mTau−/− mice (n = 8/9/group) were randomly
allocated to the PBS or LPS groups. The timeline of the
experiment is shown Figure 1A. Mice were subjected to baseline
behavioral assessment prior to being challenged with PBS or LPS.
On Day 1, they were trained to burrow food overnight in groups,
and on Day 2, they underwent baseline food burrowing testing
for 4 h, singly housed. On Day 3, mice were challenged with
LPS (100, 250, or 330 µg/kg i.v.) or PBS (1µl/g of body weight,
i.v.). Post-treatment spatial working memory performance was
assessed 4 h later in the spontaneous alternation test, and
locomotor activity was recorded as an indicator of LPS-induced
sickness effects. Mice were then immediately sacrificed by
cervical dislocation. Trunk blood was collected for quantification
of cytokine levels, in order to determine whether 4R availability
impacts upon the systemic response of hTau mice to LPS. The
brains were removed, and the hippocampi were dissected from
one hemisphere and snap-frozen for subsequent assessment of
total and phosphorylated tau levels by western immunoblotting.
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FIGURE 1 | Increasing 4R tau levels in hTau mice modulates lipopolysaccharide (LPS)-induced behavioral suppression at 4 h post-injection. Data are expressed as
means ± standard error of the mean (SEM). (A) Timeline of the experiment. Three-month-old male wild-type Wt, mTau+/−, mTau−/−, hTau/mTau+/−, and
(Continued)
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FIGURE 1 | hTau/mTau−/− mice were subjected to baseline assessment of food burrowing performance prior to receiving a tail vein injection of LPS (100, 250, or 330
µg/kg) or its vehicle (phosphate buffer saline, PBS; n = 8–9/group). Spatial working memory and LPS-induced sickness effects were tested at 4 h post-injection in the
spontaneous alternation test, the latter by measuring locomotor activity in the Y-maze, prior to blood and tissue collection. (B–D) Hippocampal tau isoform levels were
determined by western immunoblotting (B). Breeding hTau mice on a heterozygous murine tau (mTau) knockout background significantly increased hippocampal 4R
tau levels (C), without altering 3R tau levels (D). Since LPS had no statistically significant effects on tau isoform levels, which are genetically determined, treatment
groups were subsequently pooled for each genotype, for the sake of clarity. n = 34–36 per genotype. Pairwise comparisons: #p < 0.05; ##p < 0.01; ###p <
0.0001. (E–F) In the absence of immune stimulation, food burrowing behavior was impaired (E) and body weight was reduced (F) in hTau mice, regardless of the
mTau background. n = 34–36 per genotype. Pairwise comparisons: #p < 0.05; ##p < 0.01; ###p < 0.0001. (G) Four hours after inoculation with systemic LPS,
exploratory drive in the spontaneous alternation test, assessed through the distance moved, was suppressed in all genotypes, but in a dose-dependent manner.
hTau/mTau+/− mice and their heterozygous mTau knockout (mTau+/−) littermates were more susceptible to the lowest LPS dose, but, unlike what was seen in the
other three genotypes, they did not show further behavioral suppression with increasing LPS doses. n = 8–9/group. Pairwise comparisons: **p < 0.01; ***p < 0.0001
vs. PBS.
For six animals per group, the other hemisphere was snap-
frozen for analysis of sarkosyl-insoluble tau species, while for the
remaining two to four animals, one hemisphere was fixed in PFA
for 6 h and paraffin embedded for immunohistological analyses
of tau.
Persistence of LPS Effects on Systemic
Inflammation, Behavioral Sickness, and Tau
Phosphorylation at 24 h Post-Inoculation
We determined the persistence of LPS-induced alterations
in tau pathology in 3-month-old male Wt, mTau+/−, and
hTau/mTau+/− mice 24 h following LPS administration, as
hTau/mTau−/− mice were less affected by the immune challenge.
The timeline of the experiment is illustrated Figure 5A. Mice
first underwent a grouped food burrowing practice (Days 1–4),
followed, on Day 5, by baseline assessment of food burrowing
performance overnight and spontaneous alternation behavior.
On Day 8, mice were administered with either PBS or 250 µg/kg
LPS (i.v., n = 9–10/group), as this was the most effective dose,
and assessed for LPS-induced sickness in the food burrowing test
overnight and in the spontaneous alternation test 24 h after the
injection. They were then culled by cervical dislocation; trunk
blood and brain tissue were collected as described above.
Behavioral Assessment
Food Burrowing
Food burrowing is a species-specific behavior largely dependent
on the integrity of the hippocampus (55), which is suppressed in
response to systemic inflammation (56, 57) and is sensitive to the
progression of tau pathology in hTau mice (49). The protocol was
adapted from one previously described (49). For the overnight
practice of food burrowing in groups, a jar containing 50 g of
food pellets broken into small pieces was added to the home
cage between 17:00 and 18:00 and removed between 09:00 and
10:00 the next day. To assess food burrowing performance, singly
housed animals were provided with a jar containing 50 g of food
pellets overnight, environmental enrichment, and ad libitum
access to food and water. The amount of food displaced from the
jar was recorded, expressed as a percentage of the 50 g provided,
and used as a measure of food burrowing performance.
Spontaneous Alternation
Spontaneous alternation was used as previously described (49)
to assess spatial working memory and exploratory drive. The
latter is suppressed in response to LPS-induced sickness and is
a potential confounding factor for the assessment of cognitive
effects (58). The Y-maze comprised three transparent Plexiglas
arms (41.5 cm in length and 6 cm in width surrounded by 15 cm
high transparent Perspex walls) at a 120◦ angle from each other
each. The start point (6 × 7.5 cm) was located in the center of
the maze, and the mice were allowed to freely explore the three
arms over 5min. The total distance moved in the whole maze
was automatically tracked using the Ethovision software (v.10,
Noldus, Wageningen, Netherlands) and used as an indication of
exploratory drive. A correct alternation entailed amouse entering
three different arms in a row. The number of alternations was
recorded manually and expressed as a percentage of alternations
to estimate spatial working memory performance.
Assessment of Tau Pathology
Western Immunoblotting
To assess tau pathology, western immunoblotting of tau
species and protein phosphatase 2A catalytic (PP2Ac)
activity was carried out on hippocampal tissue. Briefly,
tissue was homogenized in 5× radioimmunoprecipitation
assay (RIPA) buffer [50mM Tris-HCl (Sigma, #T5941),
0.1% Triton X-100 (Sigma, X100), 0.25% Na-deoxycholate
(Sigma, #D6750), 150mM NaCl (Sigma, #S3014), 1mM
Ethylenediaminetetraacetic acid (EDTA), (Sigma, #EDS)]
containing phosphatase 1mM Na3VO4 (Sigma, #S6508),
1mM NaF (Sigma, #S7920), and complete protease inhibitor
(Roche, #11697498001). Samples were then centrifuged at
20,000 Relative Centrifugal Force (RCF) for 20min and the
resulting supernatant, corresponding to the cytosolic fraction,
was collected. Total protein levels were measured using
the bicinchoninic acid (BCA) assay (Novagen, #71285) and
standardized in RIPA buffer. Samples were diluted 1:2 in
Laemmli buffer (Sigma, #3401) and heated at 100◦C for 5min to
denature. For determination of PP2A activity, prior to heating
at 100◦C, samples were pre-treated with 0.1M NaOH for 30min
at 37◦C followed by neutralization with HCl to completely
demethylate samples. The PP2Ac subunit is regulated by
methylation of its 309L residue, which induces its activation. The
PP2Ac antibody 05-421 (Merck) binds PP2Ac at this position
but cannot if the molecule is methylated, binding only inactive
PP2A (59).
Following denaturation at 100◦C, 15 µg of protein was
resolved on 7.5% Criterion TGX gels (BioRad Laboratories)
and transferred to Amersham Protran 0.45NC nitrocellulose
membranes (GE Healthcare, #10600002). Membranes were
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blocked with 5% milk in Tris buffered saline (TBST; 0.1%
tween 20) for 1 h at room temperature and probed overnight
at 4◦C in blocking buffer with anti-rabbit GAPDH (1:40;000,
G8795; Sigma Aldrich) as a loading control; anti-mouse
Tau46 (1:500, T9450; Sigma Aldrich) for total tau; anti-
mouse CP13 (1:500, pS202) and anti-mouse PHF1 (1:500,
pS396/404), both generously gifted by Prof. Peter Davies (NY,
USA), for early- and late-pathological-stage tau phosphorylation,
respectively; anti-mouse RD3 (1:1,000, 05-803, Millipore) and
anti-mouse RD4 (1:500, 05-804, Millipore), for 3R and 4R
tau isoforms, respectively; and anti-mouse PP2A (1:5,000, 05-
421, Millipore) targeting PP2Ac. After washing with TBST,
membranes were incubated with infrared fluorescent secondary
antibodies IRDye 680RD Goat anti-Rabbit (1:15,000, 926-68071;
LI-COR) and IRDye 800CW Goat anti-Mouse (1:15,000, 926-
32210; LI-COR) in blocking buffer for 1 h at room temperature.
Blots were scanned and analyzed using the Odyssey infrared
imaging system (LI-COR Biosciences). Band intensities were
normalized to GAPDH. In the dose–response experiment,
a ratio between either pS202 or pS396/404 and tau46 was
calculated to provide a ratio of phosphorylated: total tau.
For PP2A activity, the ratio between non-NaOH and NaOH
treated samples was calculated to provide a ratio of inactive:
total PP2Ac.
Tau Aggregation
Aggregated tau was assessed by isolating insoluble tau via a
sarkosyl extraction method validated in house using rtg4510
mice. Hemibrains were homogenized in 11× (w/v) ice-cold
homogenization buffer [high-salt and -sucrose solution: 50mM
Tris-HCl (pH 7.5, Sigma, #T2319), 10% sucrose (Fisher, #57-
50-1), 5mM EDTA (Sigma, T9285), 800mM NaCl (Sigma,
#S1679), okadaic acid (Merck, #459620), α2-macroglobulin
(Sigma, #10602442001), and Halt protease and phosphatase
inhibitors (Thermo Scientific, #78440)]. The homogenates were
then spun at 6,000G for 15min at 4◦C and the supernatant saved.
The pellet was re-suspended in 5× (w/v) homogenization buffer
and mixed with the previously collected supernatant, producing
the total homogenate fraction. Total protein concentrations were
then determined with the BCA assay to ensure that sarkosyl
extraction of insoluble tau was carried out using an equal amount
of proteins in all mice. Total homogenates were then diluted to 5
µg/µl in homogenization buffer and centrifuged at 14,000G for
15min at 4◦C. The total homogenate supernatant was collected
(S1) and the pellet (P1) discarded. The S1 fraction was incubated
in 1% sarkosyl for 1 h at room temperature and centrifuged at
160,000G for 30min at 4◦C, and the resulting sarkosyl-soluble
supernatant (S2) was collected. A wash spin was conducted
by adding 2ml of homogenization buffer to the pellet and
centrifuging again at 160,000G for 30min. The pellet was then re-
suspended in a solubilization buffer (50mM Tris-HCl, 2.3% SDS,
1mM EDTA, and Halt protease and phosphatase inhibitors),
providing the sarkosyl-insoluble fraction (P2). Fractions were
stored at −80◦C until use for western immunoblotting of S1
and P1 fractions with anti-mouse Tau46 for total tau and anti-
mouse PHF1 for late-pathological-stage tau phosphorylation, as
described above, but with sarkosyl-insoluble P2 fractions being
resolved on 4–12% gels.
Immunohistochemical Assessment of Tau Pathology
Serial coronal sections 7µm thick were cut throughout
the hippocampus using a microtome (Microtome Slee Cut
4060), mounted onAPES (3-aminopropyltriethoxysilane)-coated
slides, and dried overnight at 40◦C. For immunostaining
of tau species, antigen retrieval was performed in boiling
sodium citrate buffer (10mM tri-sodium citrate, pH 6.0,
Fischer #S/3320/53) for 20min. Endogenous peroxidases were
then quenched in 3% H2O2 in methanol for 5min. Brain
slices were blocked for 1 h at room temperature (RT) using
mouse-on-mouse Immunoglobulin G (IgG) blocking reagent
(Vector, #MKB-2213). Primary antibody incubation with anti-
mouse Tau46 (1:400), CP13 (1:25, pS202), or PHF1 (1:25,
pS396/404) in blocking buffer was carried out overnight at
4◦C. Secondary antibody incubation consisted of biotinylated
horse anti-mouse secondary antibody (1:200 in blocking
buffer, Vector Laboratories, #BMK-2202), applied for 1 h
at RT. Tissue was then washed, exposed to ABC-HRP
(Vectastain Elite ABC Kit R.T.U, Vector Labs, cat. nr. PK-
7100) and labeled with DAB (3,3′-Diaminobenzidine) peroxidase
substrate (Vector Labs cat. SK-4100) according to manufacturer’s
instructions, and finally, counterstained using hematoxylin.
Digital focused photo-scanning images were then acquired
using a Hamamatsu NanoZoomer-XR 2.0-RS C10730 digital
scanning system with time delay integration (TDI) camera
technology (Hamamatsu Photonics K.K. Systems, Japan) at 20×
magnification and visualized using NDP.view2 (NanoZoomer
Digital Photography). Tau localization was assessed qualitatively.
Multiplex
Plasma levels of IL-1β, IL-6, IL-10, interferon gamma (IFN-
γ), and TNFα were determined using the Bio-Plex ProTM
Mouse Cytokine 23-Plex, Group I assay, and Bio-Plex array
reader, and analyzed using the Bio-Plex Manager Software
(Bio-Rad Laboratories, Berkeley, CA, USA) according to the
manufacturer’s instructions. The cytokine panel was designed to
provide a measure of key cytokines known to respond to LPS and
to play a role in AD.
Data Analysis
Data are presented as mean ± SEM (standard error of the
mean). ANOVAs and planned comparisons, decided a priori,
were carried out using InVivoStat (60) to compare relevant
experimental groups. The significance of relevant pairwise
comparisons was determined by using ANOVAs with post hoc
Fisher’s least significant difference (LSD), rather than post hoc
tests with correction for multiple comparisons, because the
whole experimental design was planned to test a few specific
hypotheses that are reflected by the small subset of chosen
planned comparisons. Therefore, the risk of false positives (Type
1 errors) is unlikely and further reduced by using the variance
estimate generated by the ANOVA models, using all animals
within the experiment. This approach also has a lower chance of
declaring false negative results (Type 2 errors) arising from the
high number of possible comparisons. The number of arm entries
was used as a covariate for the analysis of spontaneous alternation
performance to control for confounding effects of LPS-induced
behavioral suppression. Baseline behavioral and body weight
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data, as well as analysis of tau isoforms and species in hemibrains
from 9-month-old mice, were subjected to one-way ANOVAs
with genotype as a between factor, followed, where appropriate,
by planned comparisons. The following pairwise comparisons
were decided a priori (7 out of 10 possible comparisons): (i) Wt
vs. each of the four genetically altered groups to test for genotype
differences; (ii) hTau/mTau+/− and hTau/mTau−/− vs. their
respective mTau control, to test for human tau expression within
each mTau genotype; and (iii) hTau/mTau+/− vs. hTau/mTau−/−
to test for the impact of 4R tau availability on the hTau phenotype.
The effects of LPS on tau isoforms and pathology as well as
cytokine data were assessed by two-way ANOVAs with genotype
and either doses (4 h time point) or treatment (24 h time point) as
between-subject factors, followed, where appropriate, by planned
comparisons. For analyses of tau species and 4R tau, mTau−/−
mice were excluded, as they do not express tau. Analyses of 3R tau
were only conducted in the two hTau models, as non-genetically
altered mice do not express 3R tau. To account for gel-to-gel
variability in western immunoblotting data, a randomized block
analysis of variance was conducted, followed, when appropriate,
by planned comparisons. Data for phosphorylated:total tau
ratios were log transformed to normalize the distribution. The
following pairwise comparisons were decided a priori (39 out
of 190 possible comparisons for the 4 h time point and 6 out
of 15 possible comparisons for the 24 h time point): (i) PBS-
treatedWt vs. each of the four genetically altered groups to test for
genotype differences in the absence of immune stimulation; (ii)
PBS-treated hTau/mTau+/− and, if appropriate, hTau/mTau−/−,
vs. their respective PBS-treated mTau control, to test for the
effect on human tau expression within each mTau genotype;
(iii) PBS- vs. LPS-treated mice for each LPS dose within each
genotype to test for differences caused by systemic inflammation
with LPS; (iv) for the 4 h time point only, hTau/mTau+/− vs.
hTau/mTau−/− for each LPS dose to test for the impact of 4R tau
availability on the hTau phenotype in the absence and presence of
immune stimulation; and (v) LPS doses within each genotype to
test for dose-dependent effects. To assess the persistence of LPS-
induced sickness at 24 h post-inoculation, we compared baseline
and post-injection data using two-way ANOVAs with genotype
and treatment as between-subject factors and repeated measures
over time, followed by planned comparisons. The following
pairwise comparisons were decided a priori (8 out of 66 possible
comparisons): (i) Wt vs. each of the two genetically altered
groups prior to injection with PBS or LPS, to test for genotype
differences at baseline, and (ii) baseline vs. post-injection data
within each experimental group to test for the effect of the PBS or
LPS challenge and/or repeated testing. P ≤ 0.05 was considered
statistically significant.
RESULTS
Increased 4R Tau Availability in
hTau/mTau+/− Exacerbates Tau
Hyperphosphorylation Without Worsening
Behavioral Disturbances
We have previously shown that hTau mice bred on
a heterozygous mTau knockout background develop
behavioral and pathological features of tauopathies (48).
Using hemibrains from 9-month-old mice, we first aimed to
determine whether this breeding strategy impacted on tau
aggregation, but neither hTau/mTau+/− nor hTau/mTau−/−
mice exhibited aggregated tau (Supplementary Figure 1G).
Next, we used this tissue for verification of the expected
increase in 4R tau (Supplementary Figure 1B) without
affecting 3R tau levels (Supplementary Figure 1C) in
hTau/mTau+/− mice. This preliminary experiment on a
limited number of animals also suggested that increased
4R tau availability was associated with elevated levels of
total, early-, and late-pathological-stage phosphorylated
tau (Supplementary Figures 1D,E).
To address the possible impact of tau isoform ratio imbalance
in the hippocampal response and sickness response to systemic
inflammation, hTau mice were therefore bred on either an
mTau+/− or mTau−/− background and dosed with PBS or
LPS at 3 months of age. We first confirmed that hippocampal
levels of 4R tau (Figure 1C) were significantly affected by the
genotype [F(3, 117) = 19.09, p < 0.0001], regardless of treatment
[LPS doses: F(3, 117) = 0.92, p = 0.43; genotype × LPS doses:
F(9, 117) = 0.11, p = 0.99]. Accordingly, hippocampal levels
of 4R tau were reduced by half in mTau+/− compared to Wt
mice (p = 0.0004) and significantly higher in hTau/mTau+/−
than in both mTau+/− (p < 0.0001) and hTau/mTau−/− (p
< 0.0001, Figure 1C), while 3R levels did not differ between
hTau/mTau+/− and hTau/mTau−/− mice [F(1, 48) = 0.23,
p = 0.63, Figure 1D], regardless of treatment [LPS doses:
F(3, 48) = 1.23, p = 0.31; genotype × LPS doses: F(3, 48) =
0.02, p = 0.99], confirming our preliminary findings in the
whole brain of 9-month-old mice (Supplementary Figure 1).
Next, we verified the presence of pathological tau features in
3-month-old mice using data from PBS-treated mice. This
also indicated that increasing 4R tau levels in hTau mice were
associated with elevated hippocampal tau phosphorylation
at the pS202 (p = 0.003 vs. hTau/mTau−/− mice; Figure 3B)
and pS396/404 epitopes (p < 0.0001 vs. hTau/mTau−/−
mice; Figure 3C), although total tau levels were not affected
(Figure 3D). PBS-treated hTau/mTau+/− also presented
with an elevated pS202:tau46 ratio compared to both PBS-
treated Wt (p = 0.03) and mTau−/− (p = 0.0002) mice
(Supplementary Figure 4A), but the ratio of late-stage
phosphorylated tau to total tau was not different between
the genotypes (Supplementary Figure 4B). Tau redistribution
is another pathological feature of tauopathies, whereby
hyperphosphorylated tau dissociates from microtubules and
relocates from the axon to the somatodendritic compartment
(61). We therefore examined whether this also occurred in
3-month-old hTau/mTau+/− mice using pS202 immunostaining,
as a small ring of positive CP13 is expected around cell bodies
upon somatodendritic tau redistribution (36). While there was
mild evidence of tau in the somatodendritic compartment
of both Wt and mTau+/− mice, strong CP13 positive
rings were observed in hTau/mTau+/− and hTau/mTau−/−
mice (Supplementary Figure 2), indicating redistribution of
phosphorylated tau and confirming our previous observation
in 6-month-old hTau mice bred on a heterozygous mTau
knockout (48).
Frontiers in Immunology | www.frontiersin.org 7 March 2020 | Volume 11 | Article 293
Barron et al. 4R Tau Promotes Tau Dephosphorylation
We have previously shown that the food burrowing task is
the most sensitive test to assess early behavioral perturbations
in hTau mice bred on either an mTau−/− (49) or mTau+/−
(48) background, and that this behavior is suppressed 4 h after
inoculation with LPS in an APP/PS1 mouse model of AD and
their Wt littermates (57). Here, mice were assessed for food
burrowing performance prior to being challenged with PBS or
LPS, and we found that the severity of the food burrowing
deficit in 3 -month-old hTau mice was independent of the mTau
genotype [genotype: F(4, 171) = 3.89, p = 0.005; hTau/mTau
+/−:
p = 0.002 vs. Wt; hTau/mTau−/−: p = 0.02 vs. Wt; Figure 1E].
We also found that both hTau models weighed less than their
Wt and respective mTau knockout littermates [genotype: F(4, 171)
= 6.91, p < 0.0001; hTau/mTau+/−: p = 0.003 vs. Wt and p
= 0.0002 vs. mTau+/−; hTau/mTau−/−: p = 0.004 vs. Wt and
p = 0.0009 vs. mTau−/−; Figure 1F]. Behavioral performance
in the spontaneous alternation test, however, did not differ
between PBS-treated mice of all five genotypes (Figure 1G for
distance moved and Supplementary Figure 3A for alternation
rate). Thus, while modulation of 4R tau availability in hTau
mice impacts on tau phosphorylation, this is not associated with
differences in early behavioral and physiological disturbances.
4R Tau Availability Modulates the
Susceptibility to LPS-Induced Sickness in
hTau Mice
To determine whether the systemic inflammation-induced
sickness in hTau mice was affected by increasing 4R tau
availability, locomotor activity was tracked in the spontaneous
alternation task 4 h after inoculation with LPS. The distance
moved in the Y-maze was dose-dependently depressed by LPS
[F(3, 153) = 28.26; p < 0.0001] regardless of the genotype [F(4, 153)
= 1.56, p = 0.018; Figure 1G], but the lowest LPS dose (100
µg/kg) was only significantly effective in inducing behavioral
suppression in hTau/mTau+/− mice (p = 0.0006 vs. PBS) and
their heterozygousmTau knockout littermates (p= 0.001 vs. PBS)
without declining further with increasing LPS doses, in contrast
to other genotypes (Figure 1G). This suggests that 4R tau levels
modulate the sickness response to low LPS doses. Spontaneous
alternation performance, however, was not significantly altered
by LPS [LPS doses: F(3, 140) = 0.58, p = 0.63; genotype × LPS
doses: F(12,140) = 1.51, p= 0.13; Supplementary Figure 3).
4R Tau Availability Limits the Cytokine
Response to Higher LPS Doses in hTau
Mice at 4 h Post-Inoculation
To determine whether elevated 4R tau affects the extent of
the cytokine response to systemic LPS administration, we
quantified circulating levels of the pro-inflammatory cytokines
IL-1β, IL-6, INFγ, and TNFα and prototypical anti-inflammatory
cytokine IL-10. Indicating a strong pro-inflammatory response
had occurred in response to all LPS doses, serum concentrations
of all cytokines were significantly elevated [IL-1β: F(3, 119) =
44.95, p < 0.0001, Figure 2A; INFγ: F(3, 121) = 45.39, p < 0.0001,
Figure 2B; TNFα: F(3, 121) = 48.37, p < 0.0001, Figure 2C; IL-
6: F(3, 120) = 47.40, p < 0.0001, Figure 2D; and IL-10: F(3, 121)
= 45.07, p < 0.0001, Figure 2E], with little variations between
doses within each genotype. Four hours after inoculation with
the 330 µg/kg dose, however, LPS-induced secretion of INFγ
and IL-10 were significantly lower in hTau/mTau+/− than in
hTau/mTau−/−mice (Figures 2B,E, respectively), suggesting that
4R tau availability modulates the cytokine response to systemic
immune stimulation in a dose-dependent manner.
4R Tau Availability Exacerbates the Rapid
Tau Dephosphorylation Induced by LPS in
hTau Mice
Next, we determined whether low doses of LPS affect
hippocampal tau phosphorylation and the extent to which
this can be modulated by 4R tau availability in hTau mice.
We used western immunoblotting to quantify the levels of
tau phosphorylation epitopes pS202 and pS396/404, which are
predominantly associated with early-stage (18) and late-stage
(62) tau pathology, respectively. They have been found to
be induced by septic doses of LPS in tau models in vivo
(35, 37, 63). In contrast, we found, 4 h after inoculation
with systemic LPS, reduced hippocampal levels of pS202 and
pS396/404 in hTau/mTau+/− mice regardless of the dose (p
< 0.05 vs. PBS-treated hTau/mTau+/− mice in all cases,
Figures 3B,C), while in hTau/mTau−/− mice, LPS selectively
lowered tau phosphorylation at the pS202 epitope at the lowest
(100 µg/kg) dose (p < 0.05 vs. PBS-treated hTau/mTau−/−
mice, Figure 3B). In hTau/mTau+/−, LPS also significantly
lowered the pS202:tau46 ratio at the 100 and 250 µg/kg
doses (p = 0.008 and p = 0.004 vs. PBS-treated mice,
respectively, Supplementary Figure 4A), and pS396/404:tau46
ratio at the 100 µg/kg dose only (p = 0.04 vs. PBS-treated
mice, Supplementary Figure 4B), but significant reductions in
the phosphorylated: total tau ratios were particularly observed in
Wt mice at all LPS doses (Supplementary Figures 4A,B), despite
the lack of significant alterations in tau species (Figures 3A–D).
Thus, the enhanced tau phosphorylation caused by increased 4R
tau levels is associated with a greater response of hTau/mTau+/−
mice to low LPS doses. Total tau levels remained constant,
regardless of the genotype (Figure 3D), suggesting that tau
dephosphorylation is the likely mechanism underlying reduced
tau phosphorylation following LPS administration. We therefore
looked at whether LPS modulated the activity of PP2Ac, the
most important tau phosphatase in the central nervous system
(CNS), by quantifying inactive and total hippocampal PP2Ac
levels by western immunoblotting. However, LPS failed to
significantly impact PP2Ac activity at 4 h in all genotypes,
although there was a trend for a selective increase in PP2Ac
activity in hTau/mTau+/− mice, suggested by the non-significant
reduction in the ratio of inactive to total PP2Ac seen with
all three LPS doses (Figure 4B). Furthermore, LPS, regardless
of the dose, failed to induce tau aggregation in all genotypes,
as evidenced by the absence of sarkosyl-insoluble total and
pS396/404 tau in the whole brain of 3-month-old mice
(Supplementary Figure 5A), where we confirmed the impact
of 4R Tau availability on soluble levels of these two markers,
seen in their hippocampi (Figures 1A,C,D). All LPS doses
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FIGURE 2 | LPS-induced serum cytokines at 4 h post-injection. Three-month-old male Wt, mTau+/−, mTau−/−, hTau/mTau+/−, and hTau/mTau−/− mice were
challenged with LPS [100, 250, or 330 µg/kg, intravenously (i.v.)] or its vehicle PBS. Their serum was collected 4 h later, immediately after behavioral assessment, for
measurement of induced levels of pro- and anti-inflammatory cytokines. At this time point, significant increases in circulating levels of the pro-inflammatory cytokines
interleukin 1β (IL-1β, A), interferon gamma (IFN-γ, B) and tumor necrosis factor alpha (TNFα, C); of IL-6 (D), which has both pro- and anti-inflammatory effects; and of
the anti-inflammatory cytokine IL-10 (E) were observed regardless of the genotype and LPS dose. At the highest LPS dose (330 µg/kg), however, LPS-induced IFN-γ
(B) and IL-10 (E) were significantly higher in hTau/mTau−/− than seen in hTau/mTau+/−, suggesting that expression of 4R mTau in hTau mice dampens the cytokine
response to stronger immune stimulations. Data are expressed as means ± SEM. n = 5–9/group. Pairwise comparisons: *p < 0.05, **p < 0.01, ***p < 0.0001 vs.
PBS and #p < 0.05, ##p < 0.01 vs. hTau/mTau−/− mice.
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FIGURE 3 | LPS-induced tau dephosphorylation at 4 h post-injection. Three-month-old male Wt, mTau+/−, mTau−/−, hTau/mTau+/− and hTau/mTau−/−, mice were
challenged with LPS (100, 250, or 330 µg/kg, i.v.) or its vehicle PBS. Their brains were collected 4 h later, immediately after behavioral assessment, for
(Continued)
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FIGURE 3 | measurement of phosphorylated tau at the pS202 and pS396/404 epitopes and total tau (tau 46), by western immunoblotting (A). In the absence of
immune stimulation, expression of 4R mTau in hTau mice (hTau/mTau+/−) exacerbated pS202 (B) and pS396/404 (C) tau phosphorylation. Pairwise comparisons:
##p < 0.01; ###p < 0.0001 vs. hTau/mTau−/− mice. In response to LPS, tau dephosphorylation occurred in hTau/mTau+/−, regardless of the dose, at both
epitopes (B,C), while in hTau/mTau−/−, the 100 µg/kg dose was selectively effective in reducing pS202 levels (B), but total tau levels were unaltered by LPS (D). This
indicates that increasing 4R tau in hTau mice increased their tau phosphorylation potential at baseline as well as tau dephosphorylation potential in response to
immune stimulation. Data are expressed as means ± SEM. n = 7–9/group. Pairwise comparisons: *p < 0.05; **p < 0.01; ***p < 0.0001 vs. PBS.
FIGURE 4 | LPS failed to significantly increase protein phosphatase 2A catalytic (PP2A) activity. Three-month-old male Wt, mTau+/−, mTau−/−, hTau/mTau+/−, and
hTau/mTau−/− mice were challenged with LPS (100, 250, or 330 µg/kg, i.v.) or its vehicle PBS. Their brains were collected 4 h later, immediately after behavioral
assessment. Since we found that LPS was able to dephosphorylate tau in both hTau models, we also assessed activity of the main tau phosphatase in the brain
(PP2Ac) by western immunoblotting of inactive and total PP2Ac levels (A). PP2A activity was estimated by the ratio of inactive: total PP2Ac (B), whereby a reduction
in this ratio would indicate increase PP2A activity. Although this ratio tended to be lower in LPS-treated hTau mice, regardless of the mTau phenotype, this failed to
reach statistical significance. Data are expressed as means ± SEM. n = 7–9/group.
indeed lowered whole-brain levels of phosphorylated tau at
the pS396/404 epitope in hTau/mTau+/− (all p < 0.0002
vs. PBS-treated hTau/mTau+/−), but not hTau/mTau+/−, mice
(Supplementary Figure 5C) without affecting total tau levels
(Supplementary Figure 5D).
LPS-Induced Tau Dephosphorylation
Persists for at Least 24h in hTau/mTau+/−
Mice
All together, the data reported above suggest that reducing
the predominance of 3R tau by increasing 4R tau availability
exacerbates tau hyperphosphorylation in 3-month-old hTau
mice, as well as the tau dephosphorylating effect of low LPS
doses, 4 h after inoculation. We therefore next investigated
in hTau/mTau+/− mice the persistence of LPS effects at
the 250 µg/kg dose (Figure 5A), which produced robust
pro-inflammatory response and tau dephosphorylation. We
chose a 24 h time point, which is expected to correspond
to the resolution of the pro-inflammatory cytokine response
following acute LPS administration in mice (64). We found
that LPS-treated hTau/mTau+/− mice and their LPS-treated Wt
and mTau+/− littermates were still experiencing LPS-induced
sickness, manifested by a significant weight loss in all genotypes
[∼ 10%; p < 0.0001 vs. baseline pre-injection weight in all cases;
treatment × time: F(1, 53) = 163.89, p < 0.0001; Figure 5B],
as well as suppression of food burrowing behavior [p < 0.03
vs. baseline pre-injection performance in all cases; treatment ×
time: F(1, 53) = 41.16, p < 0.0001; Figure 5C]. However, while
the injection and/or repeated testing attenuated spontaneous
exploration of the Y-maze during the spontaneous alternation
test [time: F(1, 52) = 122.07, p < 0.0001; Figure 5D], the
reduction in the distance moved in the apparatus was also
greater in LPS-treated than PBS-treated mice [treatment ×
time: F(1, 52) = 8.07, p = 0.006; ∼ −23–29% in PBS-treated
mice, all p < 0.03 vs. baseline performance; and −52–61%
in LPS-treated mice, all p < 0.0001 vs. baseline performance;
Figure 5D], indicating residual sickness effects of the immune
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FIGURE 5 | Persistence of systemic LPS effects in hTau/mTau+/− mice at 24 h post-injection. Data are expressed as means ± SEM. (A) Timeline of the experiment.
Three-month-old male Wt, mTau+/− and hTau/mTau−/− mice were subjected to baseline assessment of food burrowing and spontaneous alternation performance
prior to receiving a tail vein injection of LPS (250 µg/kg) or its vehicle (PBS; n = 9–10/group). Induced sickness effects were tested at 24 h post-injection by measuring
(Continued)
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FIGURE 5 | body weight loss, exploratory drive in the spontaneous alternation test, and food burrowing behavior prior to blood and tissue collection. Sickness
symptoms were still present 24 h after LPS administration, as reflected by the body weight loss (B) and suppression of food burrowing behavior (C) seen in
LPS-treated mice, regardless of the genotype. The reduction in performance seen in PBS-treated mice indicated that exploratory drive in the spontaneous alternation
test was affected by repeated testing, but this was more pronounced in LPS-treated mice (D), also indicating residual sickness effects; however, spontaneous
alternation performance did not differ from baseline levels (E). (F–J) LPS-induced circulating cytokines. Upper segment corresponds to the range of induced levels
measured 4 h after inoculation with LPS. Indicating a resolution of the pro-inflammatory cytokine response to LPS, a return to baseline values was observed at the
24 h time point for IL-1β (F), IFN-γ (G), and TNFα (H). Circulating levels of IL-6, known to exert anti-inflammatory effects at a low dose, remained elevated in all
genotypes but to a much lower extent than seen at the 4 h time point (I). Concentrations of the anti-inflammatory cytokine IL-10 were also still elevated but at levels
close to those measured at 4 h post-LPS and to a lower extent in hTau/mTau−/− mice than in Wt and mTau+/− mice (J). This indicates than sickness symptoms
persist at 24 h after LPS administration, despite the resolution of the systemic pro-inflammatory cytokine response. We also replicated the characteristic food
burrowing deficit of hTau mice in the absence of immune stimulation (C). Pairwise comparisons: *p < 0.05, **p < 0.01, ***p < 0.0001 vs. PBS or baseline; ##p <
0.01 vs. other genotypes. n = 9–10 per group.
challenge. Spontaneous alternation performance, a measure of
spatial working memory, was not affected (Figure 5E). Although
circulating levels of the pro-inflammatory cytokines IL-1β,
INFγ, and TNFα had returned to baseline values in all three
genotypes (Figures 5F–H), the pro-inflammatory cytokine IL-6,
known to exert anti-inflammatory effects at low doses (65, 66),
remained elevated in all three genotypes 24 h after systemic LPS
administration [treatment: F(1, 51) = 45.16, p < 0.0001], albeit
to a much lesser extent than observed at the 4 h time point
(Figure 5I). Concentrations of the anti-inflammatory cytokine
IL-10 remained elevated in all three genotypes [treatment: F(1, 51)
= 76.34, p < 0.0001] at levels closed to those measured at the 4 h
time point, but to a lower extent in LPS-treated hTau/mTau+/−
mice than in LPS-treated Wt (p < 0.0009) and mTau+/− (p <
0.0018) mice [genotype × treatment: F(2, 51) = 3.93, p = 0.026;
Figure 5J]. Furthermore, at 24 h post-injection, hippocampal tau
dephosphorylation was still seen in LPS-treated hTau/mTau+/−
mice at both the pS202 (p = 0.01 vs. PBS-treated mice,
Figures 6A,B) and pS396/404 (p = 0.04 vs. PBS-treated mice,
Figures 6A,C) epitopes, while total levels of tau (Figures 6A,D)
and PP2Ac activity (Figures 6E,F) remained unaltered. We again
assessed sarkosylinsoluble tau at 24 h post-inoculation with
LPS, and there was no evidence of either total or pS396/404
tau in sarkosyl fractions, regardless of treatment (Figure 6G),
indicating that LPS did not induce tau aggregation (Figure 6F).
DISCUSSION
To investigate whether reducing the predominance of the toxic
3R Tau isoform affects susceptibility to systemic inflammation
and LPS-induced changes in tau phosphorylation, we increased
4R tau availability in hTau mice by breeding them on a
heterozygous mTau knockout background, as adult mTau
consists solely of 4R tau (67). We found in 3-month-old mice
that increasing 4R availability in hTau mice exacerbated tau
hyperphosphorylation but not total tau in the absence of immune
stimulation as well as tau dephosphorylation in response to
all three doses of LPS tested. The increased phosphorylation
potential at baseline was not accompanied by differences in
early behavioral and physiological disturbances characteristic
of hTau mice, but the greater dephosphorylation potential of
hTau/mTau+/− under immune stimulation was associated with
a stronger acute behavioral sickness at the lowest (100µg/kg
dose) and milder sickness and cytokine responses to the highest
(330µg/kg) LPS dose.
The predominance of 3R tau has been linked to the
pathogenesis of tauopathies, correlating with the severity of
NFT pathology in the post-mortem AD brain and driving
pathological changes in hTau mice. Based on recent reports
showing that increasing 4R tau levels without changes in 3R tau
prevented the development of cognitive deficits in these mice, as
well as the accumulation of insoluble and phosphorylated tau,
without altering total tau levels (46), we predicted a milder tau
pathology and behavioral phenotype in hTau/mTau+/− than in
hTau/mTau−/−. In contrast, we found that the higher abundance
of the 4R tau isoform selectively increased tau phosphorylation
in 3-month-old hTau mice, although the associated increases
in phosphorylated: total tau ratios failed to reach statistical
significance. This exacerbation of pathological tau could be
resulting from differences in the extent to which we altered
the isoform ratio in the model. Espindola et al. (46) indeed
reprogrammed 3R to 4R tau isoforms to a ratio of ∼1 to mimic
the balance seen in the healthy human brain, while with our
breeding strategy, 3R tau remained the predominant isoform.
While a balance between the two isoforms may be critical to
protect from the development of tau pathology, both 3R and
4R tau were found toxic in drosophila, with isoform-specific
mechanisms of tau toxicity and phosphorylation potential (68).
There is also evidence to suggest that 4R tau is toxic in the
mouse brain. Indeed, the splicing of 3R−4R tau in hTau mice,
leading to an isoform ratio favoring 4R tau by increasing 4R tau
and correspondingly decreasing 3R tau without affecting total
tau levels, was also found to exacerbate tau phosphorylation
and behavioral abnormalities (47). Differences in structure and
function between human and mTau have been reported, but it
is unlikely that this contributes to the tau dephosphorylating
effects of increased 4R availability seen in response to LPS.
mTau mice indeed lack residues 17–28, but in vitro studies
using brain extracts from AD patients have found that this
particularly affected the binding of mTau to proteins regulating
energetic processes in neurons (69). And while several studies
have shown that the presence of mTau that is predominantly
4R delays the pathological accumulation of human tau, with
exacerbated disease progression being observed in tau models
after full removal of mTau [reviewed in (70)], we found here
that keeping 50% of mTau exacerbated tau hyperphosphorylation
in hTau mice in the absence of immune stimulation, although
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FIGURE 6 | Persistence of tau dephosphorylating effects of systemic LPS in hTau/mTau+/− mice at 24 h post-injection. Three-month-old male Wt, mTau+/−, and
hTau/mTau−/− mice were challenged with LPS (250 µg/kg, i.v.) or its vehicle PBS. Their brains were collected 24 h later, immediately after assessment of sickness
symptoms for the determination by western immunoblotting of hippocampal soluble phosphorylated tau at the pS202 and pS396/404 epitopes and total tau (tau 46)
levels (A), PP2A activity (E), and whole brain insoluble total and phosphorylated tau (G). pS202 (B) and pS396/404 (C) tau dephosphorylation persisted for at least
24 h after LPS administration, while levels of total tau (D) and PP2A activity (F) remained unaltered. There was also no evidence of insoluble tau (G). Data are
expressed as means ± SEM. Pairwise comparisons: *p < 0.05; **p < 0.01 vs. PBS.
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this was protective in response to LPS. Furthermore, in the
3xTg model of AD, endogenous mouse tau was found to
be hyperphosphorylated and to significantly co-aggregate with
human tau, while the deletion of the mTau gene in this model
lowered soluble total and phosphorylated tau, as well as insoluble
total tau, without impacting on cognition (70). This suggests
that the ability of 4R mTau to modulate pathogenic features of
human tau in mouse models is not due to species differences,
but a mechanistic study comparing the impact of 4R tau
from both species would be needed to confirm this point. We
previously reported that food burrowing is the most prominent
early behavioral deficit in hTau mice, regardless of the mTau
background (48, 49). As seen in the 3xTg model, we found here
that the expression of 4R mTau in hTau mice did not worsen the
food burrowing impairment, nor the lower body mass, despite
the increased tau phosphorylation. Whether or not this has also
an impact on tau aggregation could not be investigated here, as
we, unexpectedly, did not find evidence of insoluble total and/or
phosphorylated tau at the ages investigated. As we discussed
before (49), the C57BL/6J background was found to weaken the
phenotype of a number of disease models and could explain
the milder phenotype of hTau mice obtained from The Jackson
Laboratory, as compared to that originally described (36) on a
mixed Swiss Webster/129/SvJae/C57BL/6 background.
Altered immune status is a common feature of tauopathies
(71, 72), regardless of their classification in terms of 3R/4R
predominance. To the best of our knowledge, no study has
investigated whether specific tau isoforms differentially modulate
immune responses. 3R and 4R tau were reported to differ in
their physiological function and pathological role (68), and
interplays between tau mechanisms and immune responses
are thought to contribute to tau pathogenesis (71, 72). We
therefore hypothesized that increasing the abundance of 4R
tau would impact on tau pathology as well as on behavioral
and physiological responses to mild systemic inflammation
induced by LPS. We found here that the expression of 4R
murine in hTau mice had little impact on LPS-induced sickness
and circulating cytokine levels at 4 h post-inoculation, a time
point corresponding to the peak cytokine response (73–75),
but this may be dose dependent. Indeed, while behavioral
suppression increased in severity with raising doses of LPS in
Wt, hTau/mTau−/− mice and their mTau knockout littermates,
it was more severe in hTau/mTau+/− mice and heterozygous
mTau knockout littermates at the lowest dose used (100µg/kg)
but less severe at the highest dose (330µg/kg). In hTau/mTau+/−
mice, the latter was associated with reduced secretion of pro-
inflammatory cytokine INFγ and anti-inflammatory cytokine IL-
10. This suggests that while increasing availability of 4R Tau in
hTau mice enhanced the sickness response to the lowest low
LPS doses, it may limit the systemic impact of stronger pro-
inflammatory stimuli. LPS-induced tau dephosphorylation was
also more robust in hTau mice expressing 4R mTau, occurring
at all three doses on both pS202 and pS396/404 epitopes and
persisting for at least 24 h after inoculation with LPS.
While LPS was generally found to exacerbate tau
phosphorylation in models of tauopathies (35, 37, 63), our
data argue in favor of a protective effect of systemic LPS on tau
pathology. The strength of the immune stimulation is likely to
be a factor, as the above studies used either LPS doses more akin
to sepsis or a chronic dosing regimen. Consistent with our data,
recent studies also suggest that mild systemic inflammation may
be beneficial to tau pathology. A single 150 µg/kg LPS challenge
was found to decrease the levels of aggregated tau through
induction of the autophagy pathway in the P301S model (76).
Furthermore, collagen-induced arthritis in the 3xTg model was
reported to decrease tau phosphorylation and the number of
neurons affected by tau aggregates (77). As this arthritis model
is associated with chronic systemic inflammation that is truly
mild (78, 79), this also suggests that systemic inflammation
may not have a detrimental effect on tau pathology in AD.
Supporting a potential dose dependency in the occurrence of
protective vs. detrimental effects of LPS on tau pathology, tau
dephosphorylation occurred only at the pS202 epitope and only
at the lowest (100µg/kg) dose in hTau/mTau−/− mice, while in
hTau/mTau+/− mice, the highest (330µg/kg) LPS dose was the
least effective in reducing both pS202 and pS396/404 levels.
The mechanisms whereby LPS limits tau
hyperphosphorylation could not be identified in the present
study. It could result from either decreased kinase activation
or increased phosphatase activation. We hypothesized that
alterations in phosphatase activity were the source for tau
dephosphorylation in the current study, with PP2A the likely
culprit. PP2A accounts for about 1% of cellular content within
the brain and is the predominant phosphatase that affects tau
phosphorylation (80). LPS has been shown to induce PP2A
activation in vitro in endothelial cells (81, 82). Furthermore, LPS
and superoxide, one of the downstream products of LPS-induced
inflammation (83), have been shown to induce PP2A activation
in hippocampal slices (84, 85), indicating that LPS can directly
and indirectly induce PP2A activation within the CNS. To assess
PP2A activity in the current study, western blot analyses of the
PP2A catalytic subunit were conducted after incubation with
or without NaOH, giving a measure of inactive:total PP2Ac.
Despite the lack of significant alterations in this measure, there
was a trend for a decrease in both hTau genotypes 4 h after being
challenged with LPS. A more sensitive assay would be needed
to categorically ascertain whether changes in PP2A activity
were associated with LPS-induced tau dephosphorylation.
Various kinases have been implicated in the exacerbation of
tau phosphorylation by high LPS doses but with discrepancies
between studies (39). Increased activity of cyclin-dependent
kinase 5 and/or glycogen synthase kinase-3βwasmost commonly
found associated with LPS-induced tau hyperphosphorylation in
Wt and 3xTgmice (37, 38), but increased autophagic degradation
rather than reduced kinase activity was found associated with
the reduced tau pathology caused by a low 150 µg/kg LPS dose
in P301S mice (76). Their implication in the modulation of
LPS-induced tau dephosphorylation by 4R tau will need to be
investigated in future studies.
CONCLUSIONS
While previous studies have found that a full mTau background
prevents the development of tau pathology in the hTau model
(36), we found here that reducing mTau expression by half
exacerbates tau phosphorylation in this model, suggesting that
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the effect of 4R mTau on pathogenesis in hTau mice is dose
dependent. Our data also further demonstrate that modulation
of the 4R:3R tau isoform ratio effectively modulates disease
severity in this model. However, we are the first to show that
this also affects the impact of systemic inflammation on tau
phosphorylation, behavioral sickness, and circulating cytokine
levels. Despite leading to an increase in tau phosphorylation
potential in the absence of immune stimulation, elevated 4R
tau levels in hTau mice were also associated with an increased
tau dephosphorylation potential in response to LPS, but the
underlying mechanism of this needs to be investigated in future
studies. The attenuated systemic response of hTau/mTau+/−
mice to the highest LPS dose tested also suggests that 4R tau
may actually offer some protection against disease-exacerbating
effects of systemic inflammation.
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